Sinovac Biotech announces that the Nasdaq Hearings Panel has granted the company’s request to continue its listing on the Nasdaq Stock Market, subject to conditions focused on timely completion of its financial audit and remediation of filing delinquencies, according to a statement.
- Sinovac says it is working with its accounting firm to complete the required audit and to regain compliance with its filing obligations by May 11
To contact the reporter on this story:
To contact the editors responsible for this story:
Olivia Tam
© 2026 Bloomberg L.P. All rights ...